AU2004291457A1 - 4-substituted imidazoles - Google Patents

4-substituted imidazoles Download PDF

Info

Publication number
AU2004291457A1
AU2004291457A1 AU2004291457A AU2004291457A AU2004291457A1 AU 2004291457 A1 AU2004291457 A1 AU 2004291457A1 AU 2004291457 A AU2004291457 A AU 2004291457A AU 2004291457 A AU2004291457 A AU 2004291457A AU 2004291457 A1 AU2004291457 A1 AU 2004291457A1
Authority
AU
Australia
Prior art keywords
disease
compound according
atoms
disorders
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004291457A
Other languages
English (en)
Inventor
James Empfield
Eifion Phillips
Scott Throner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2004291457A1 publication Critical patent/AU2004291457A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2004291457A 2003-11-19 2004-11-15 4-substituted imidazoles Abandoned AU2004291457A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0303075A SE0303075D0 (sv) 2003-11-19 2003-11-19 4-substituted imidazoles
SE0303075-6 2003-11-19
PCT/SE2004/001660 WO2005049612A1 (en) 2003-11-19 2004-11-15 4-substituted imidazoles

Publications (1)

Publication Number Publication Date
AU2004291457A1 true AU2004291457A1 (en) 2005-06-02

Family

ID=29729099

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004291457A Abandoned AU2004291457A1 (en) 2003-11-19 2004-11-15 4-substituted imidazoles

Country Status (13)

Country Link
US (1) US7384954B2 (enExample)
EP (1) EP1687303A1 (enExample)
JP (1) JP2007511603A (enExample)
KR (1) KR20060100426A (enExample)
CN (1) CN1882584A (enExample)
AU (1) AU2004291457A1 (enExample)
BR (1) BRPI0416629A (enExample)
CA (1) CA2546096A1 (enExample)
IL (1) IL175438A0 (enExample)
NO (1) NO20062862L (enExample)
SE (1) SE0303075D0 (enExample)
WO (1) WO2005049612A1 (enExample)
ZA (1) ZA200604018B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0303076D0 (sv) * 2003-11-19 2003-11-19 Astrazeneca Ab 5-substituted imidazoles
JP2008524212A (ja) * 2004-12-16 2008-07-10 アストラゼネカ・アクチエボラーグ ニコチン性アセチルコリン受容体リガンド
FR2974365B1 (fr) 2011-04-20 2017-08-25 Centre Nat De La Rech Scient (C N R S) 1,2,3-triazoles 1,4-disubstituees, leurs procedes de preparation et leurs utilisations diagnostiques et therapeutiques

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226000A (en) * 1987-09-10 1991-06-25 Merck Sharp & Dohme Oxadiazolyl-azabicycloheptanes and pharmaceutical compositions
WO2002015662A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
JP2004506734A (ja) * 2000-08-21 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用のキヌクリド置換ヘテロアリール部分
US20020086871A1 (en) * 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
FR2832713B1 (fr) * 2001-11-23 2004-02-13 Sanofi Synthelabo Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
EP1562945B1 (en) 2002-11-11 2006-11-15 Neurosearch A/S 1,4-diazabicyclo(3,2,2)nonane derivatives, preparation and therapeutical use thereof

Also Published As

Publication number Publication date
SE0303075D0 (sv) 2003-11-19
BRPI0416629A (pt) 2007-01-16
US7384954B2 (en) 2008-06-10
ZA200604018B (en) 2007-11-28
EP1687303A1 (en) 2006-08-09
US20070105896A1 (en) 2007-05-10
KR20060100426A (ko) 2006-09-20
JP2007511603A (ja) 2007-05-10
CA2546096A1 (en) 2005-06-02
WO2005049612A1 (en) 2005-06-02
CN1882584A (zh) 2006-12-20
IL175438A0 (en) 2006-09-05
NO20062862L (no) 2006-08-21

Similar Documents

Publication Publication Date Title
AU784400B2 (en) New use and novel N-azabicyclo-amide derivatives
RU2233282C2 (ru) Аралкиламины фуропиридинов, способ их получения, фармацевтическая композиция на их основе и промежуточные вещества
AU2005233492B2 (en) Novel 2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydroisoindol-l-one/5,6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor
JP2005539030A (ja) ニコチン性アセチルコリン作用剤としてのアリール置換ジアザビシクロアルカン
ZA200605027B (en) Nicotinic acetylcholine receptor ligands
US7384954B2 (en) 4-substituted imidazoles
AU2004291456A1 (en) 5-substituted imidazoles
US20070191422A1 (en) Nicotinic acetylcholine receptor ligands
EP1699786A1 (en) Nicotinic acetylcholine receptor ligands
MXPA06005416A (en) 4-substituted imidazoles
EP1699802A1 (en) Nicotinic acetylcholine receptor ligands
MXPA06005415A (en) 5-substituted imidazoles
MXPA06011725A (en) Novel 2-(1-aza-bicyclo [2.2.2]oct-3-yl) -2, 3-dihydroisoindol -l-one/5, 6-dihydro-furo[2, 3-c]pyrrol -4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted